¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tumour cell"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • granulosa-theca cell tumor
    °ú¸³³­Æ÷¸·¼¼Æ÷Á¾¾ç
  • hypersensitized cell
    °ú¹Î°¨¼¼Æ÷
  • hypoxic cell sensitizer
    Àú»ê¼Ò¼¼Æ÷¹Î°¨Á¦
  • heart failure cell
    ½ÉºÎÀü¼¼Æ÷
  • HeLa cell
    Çï¶ó¼¼Æ÷
  • hair cell
    Åм¼Æ÷
  • helmet cell
    Åõ±¸¼¼Æ÷
  • helper cell
    µµ¿ò¼¼Æ÷, Á¶·Â¼¼Æ÷
  • helper cell activity
    µµ¿ò¼¼Æ÷Ȱ¼º
  • hematopoietic cell transplantation
    Á¶Ç÷¼¼Æ÷À̽Ä, Ç÷±¸Çü¼º¼¼Æ÷À̽Ä
  • hairy cell
    Åиð¾ç¼¼Æ÷
  • hairy cell leukemia
    Åм¼Æ÷¹éÇ÷º´
  • hemolytic plaque-forming cell
    ¿ëÇ÷ÆÇÇü¼º¼¼Æ÷, ¿ëÇ÷ÇöóÅ©Çü¼º¼¼Æ÷
  • hepatosplenic T-cell lymphoma
    °£ºñÀåT¼¼Æ÷¸²ÇÁÁ¾
  • heteroploid cell line
    À̼öü¼¼Æ÷°è
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • interdental cell
    û°¢Ä¡¾Æ»çÀ̼¼Æ÷, Ä¡°£¼¼Æ÷
  • interstitial cell
    »çÀÌÁú¼¼Æ÷
  • islet cell
    ¼¶¼¼Æ÷
  • islet cell carcinoma
    ¼¶¼¼Æ÷¾ÏÁ¾
  • juvenile cell
    À¯¾à¼¼Æ÷
  • killer cell
    ¼¼Æ÷µ¶¼º¼¼Æ÷
  • Kupffer¡¯s cell
    º°Å«Æ÷½Ä¼¼Æ÷, ÄíÆÛ¼¼Æ÷
  • lacunar cell
    °ø°£¼¼Æ÷
  • large cell carcinoma
    Å«¼¼Æ÷¾ÏÁ¾, ´ë¼¼Æ÷¾ÏÁ¾
  • lepra cell
    ³ªº´¼¼Æ÷
  • leukemic cell
    ¹éÇ÷º´¼¼Æ÷
  • light cell
    ¹àÀº¼¼Æ÷
  • lipoid cell
    ÁöÁú¼¼Æ÷
  • luteal cell
    Ȳü¼¼Æ÷
  • lymphoid cell
    ¸²ÇÁ°è¼¼Æ÷, ¸²ÇÁ¸ð¾ç¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • globe cell anemia
    ±¸»óÀûÇ÷±¸¼º ºóÇ÷(Ë´Ë×ËøÌ´Ë´ËÛË×Ì´).
  • globoid cell
    ±¸»ó¼¼Æ÷(ϹßÒá¬øà)
  • glomus cell
    Å丮¼¼Æ÷
  • goblet cell
    ¼úÀܼ¼Æ÷, ¹è»ó¼¼Æ÷.
  • goblet cell
    ¼úÀܼ¼Æ÷
  • golgi cell
    Å«º°¼¼Æ÷
  • gonadotrope cell
    »ý½Ä¼±Àڱؼ¼Æ÷
  • granular basal cell carcinoma
    °ú¸³ ±âÀú¼¼Æ÷¾Ï
  • granular cell
    °ú¸³¼¼Æ÷.
  • granular cell myoblastoma
    °ú¸³¼¼Æ÷±Ù¸ð¼¼ Æ÷Á¾(¡­á¬øàÐÉÙ½á¬øàðþ)
  • granular cell schwannoma
    °ú¸³¼¼Æ÷ ½´¹Ý¼¼Æ÷Á¾
  • granular cell tumo(u)r
    °ú¸³¼¼Æ÷ Á¾¾ç
  • granule cell
    °ú¸³¼¼Æ÷(¡­á¬øà).
  • granule cell
    °ú¸³¼¼Æ÷
  • granuloma,giant cell
    °Å´ë¼¼Æ÷¼º À°¾ÆÁ¾
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • cell interface
    ¼¼Æ÷»çÀ̸é, ¼¼Æ÷°£¸é (¡­ÊàØü).
  • cell junction
    ¼¼Æ÷°£¿¬Á¢(á¬øàÊàææïÈ)(°áÇÕ)
  • cell junction
    ¼¼Æ÷°æ°è, ¼¼Æ÷¿¬Á¢(¡­ææïÈ).
  • cell killing
    ¼¼Æ÷»ìÇØ
  • cell labelling technique
    ¼¼Æ÷Ç¥Áö±â¹ý
  • cell lethality
    ¼¼Æ÷Ä¡»çÀ²
  • cell like colloidal drop
    ¼¼Æ÷¾çÄÝ·ÎÀ̵å¾×Àû.
  • cell line
    ¼¼Æ÷°è, ¼¼Æ÷ÁÖ
  • cell line
    ¼¼Æ÷°è(á¬øàͧ).
  • cell line
    ¼¼Æ÷°è(á¬øàͧ).
  • cell line, established
    È®¸³¼¼Æ÷ÁÖ
  • cell loss
    ¼¼Æ÷¼Ò½Ç
  • cell loss factor
    ¼¼Æ÷¼Ò½Ç°è¼ö
  • cell lysis
    ¼¼Æ÷¿ëÇØ
  • cell mass
    ¼¼Æ÷µ¢¾î¸®, ¼¼Æ÷±«
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • Epitheloid muscle cell
    »óÇǼº±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] »óÇǾç±Ù¼¼Æ÷
  • Chromophilic cell
    »ö¼Òµë¼¼Æ÷
    [¿¾ ¿ë¾î] »ö¼ÒÈ£¼º¼¼Æ÷
  • Pigment cell
    »ö¼Ò¼¼Æ÷
    [¿¾ ¿ë¾î] »ö¼Ò¼¼Æ÷
  • Chromophobic cell
    »ö¼Ò¾Èµë¼¼Æ÷
    [¿¾ ¿ë¾î] »ö¼ÒÇø¼º¼¼Æ÷
  • Cell inclusions
    ¼¼Æ÷Æ÷ÇÔ¹°
    [¿¾ ¿ë¾î] ¼¼Æ÷Æ÷ÇÔ¹°
  • Purkinje cell
    ½ÉÀåÀüµµ±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] ½ÉÀåÀÚ±ØÀüµµ¼¼Æ÷
  • Purkinje cell
    ½ÉÀåÀüµµ±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] Ǫ¸£Å²¿¹¼¼Æ÷
  • Exocrine cell
    ¿ÜºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ÜºÐºñ¼¼Æ÷
  • Villous muscle cell
    À¶¸ð±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] À¶¸ð±Ù¼¼Æ÷
  • Chief cell
    À¸¶ä¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷
  • Milk secreting cell
    Á¥ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] À¯¼¼Æ÷
  • Purkinje cell
    Á¶·Õ¹Ú¼¼Æ÷
    [¿¾ ¿ë¾î] Purkinje¼¼Æ÷
  • Ovoid cell
    Ÿ¿ø¼¼Æ÷
    [¿¾ ¿ë¾î] ³­¿øÇü¼¼Æ÷
  • Oxyphilic cell
    È£»ê¼º¼¼Æ÷
    [¿¾ ¿ë¾î] »êÈ£¼º¼¼Æ÷
  • Lutein cell
    Ȳ(»ö)ü¼¼Æ÷
    [¿¾ ¿ë¾î] Ȳü¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
RGC radio-gas chromatography; remnant gastric cancer; retinal ganglion cell; right giant cell
RSC rat spleen cell; rested state contraction; reversible sickle-cell; right subclavian
SCAT sheep cell agglutination test; sickle cell anemia test; Sports Competition Anxiety Test
sq cell ca squamous cell carcinoma
TC target cell; taurocholate; temperature compensation; teratocarcinoma; tertiary cleavage; tetracyclin...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
auto-PBSCT Autologous peripheral blood stem cell transplantation
BCGF B Cell Growth Factor
BCR B Cell Receptor
BCR B cell Ag receptor
B-CLL B cell Type
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • labile cell
    ºÒ¾ÈÁ¤ ¼¼Æ÷
  • lacrimoethmoid cell
    ´©°ñ »ç ºÀ¿Í
  • lactotropic cell
    ÇÁ·Î¶ôƾ ºÐºñ ¼¼Æ÷
    µ¿ÀǾî=lactotro
  • lacunar cell
    ¼Ò¿Í ¼¼Æ÷
    Reed-Stemberg ¼¼Æ÷ÀÇ º¯ÇüÀ¸·Î¼­ ¶Ñ·ÇÇÑ ¼¼Æ÷¸· ¾È¿¡ Á¸ÀçÇϴ dzºÎÇÑ ¼¼Æ÷Áú¿¡ µÑ·¯½ÎÀÎ ´ÜÀÏ ÇÙÀ» °¡Áö°í ÀÖ´Ù.
  • lamina IV cell
    Á¦4Ãþ ¼¼Æ÷
    1. µÕ±Û°í »ï°¢Çü ȤÀº º° ¸ð¾çÀÇ ½Å°æ ¼¼Æ÷°¡ ³ôÀº ¹Ðµµ·Î ¹è¿­µÇ¾î ÀÖ´Ù. 2. °¡º­¿î Á¢ÃË °°Àº ³·Àº ¿ªÄ¡ÀÇ Àڱؿ¡ ¹ÝÀÀÇÑ´Ù.
  • laminar I cell
    Á¦ 1Ãþ ¼¼Æ÷
    1. ÀÛ°í Áß°£ Å©±âÀÇ ¼¼Æ÷¿Í ºÐ»êµÇ¾î ÀÖ´Â Å« ¹æÃßÇüÀÇ ¼¼Æ÷µé·Î ±¸¼ºµÈ´Ù. 2. Èİ¢ÀÇ º¼·ÏÇÑ Ç¥¸é¿¡ ÆòÇàÇÏ°Ô ¹è¿­µÇ¾î ÀÖ´Ù. 3. ¿£ÄÉÆÈ¸°, ½áºê½ºÅº½º P¸¦ ÇÔÀ¯Çϰí ÀÖ´Ù.
  • laminar II cell
    Á¦ 2Ãþ ¼¼Æ÷
  • laminar ¥± cell
    Á¦ 2Ãþ ¼¼Æ÷
    Á¦ 2ÃþÀÇ ¼¼Æ÷´Â 2Á¾·ù°¡ Àִµ¥ ÃþÀÇ ¹Ù±ù ÂÊ 1/4´Â ´õ¿í ÀÛÀº ¼¼Æ÷·Î ÅëÁõ°ú ¿­¿¡ ´ëÇÑ ¼ö¿ëü¸¦ °¡Áö°í ÀÖ°í, ¾È ÂÊ 3/4´Â Á» ´õ Å« ¼¼Æ÷·Î ¹«µ¶¼ºÀÇ ±â°è¼ö¿ëü¸¦ °¡Áö°í ÀÖ´Ù.
  • Langerhans cell
    ¶û°Ô¸£Çѽº ¼¼Æ÷, Ç¥ÇÇ¼Ó Å« Æ÷½Ä¼¼Æ÷
    µ¿ÀǾî=intrae
  • large cell
    ´ë¼¼Æ÷
    ƯÁ¤ ÀÌÀ¯°¡ ÀÖ¾î
  • LE cell
    LE ¼¼Æ÷, È«¹Ý¼º ³¶Ã¢ ¼¼Æ÷
    µÕ±Û°í, ±ÕÁú·Î º¸ÀÌ´Â ºÀÀÔü¸¦ ޽ÄÇÑ ¼º¼÷ È£Áß±¸¼º ´ÙÇÙ ¹éÇ÷±¸. ±× ºÀÀÔü ÀÚü´Â ´Ù¸¥ È£Áß±¸¿¡¼­ À¯·¡µÈ °ÍÀÌ´Ù. È«¹Ý¼º ·çǪ½º¿¡ ƯÀ¯ÇÑ °ÍÀÌÁö¸¸ °áÇÕ Á¶Á÷ÀÇ À¯»çÇÑ Áúȯ¿¡¼­µµ °üÂûµÈ´Ù.
  • lingual benign giant cell tumor
    ¾ç¼º °Å´ë ¼¼Æ÷ ¼³ Á¾¾ç
  • lupus erythematosus cell
    È«¹Ý¼º ·çǪ½º ¼¼Æ÷, È«¹Ý¼º ³¶Ã¢ ¼¼Æ÷
  • M-cell
    M ¼¼Æ÷
  • malignant plasma cell
    ¾Ç¼º ÇüÁú ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
tumour promoter <molecular biology, oncology> Agent that in classical studies of carcinogenesis in rodent skin was able to increase the sensitivity of tumour formation by a previously applied primary carcinogen, but was unable to induce tumours when used alone.
Important example was croton oil, active ingredients of which are now believed to be phorbol esters. These are believed to act as analogues of diacylglycerols and may activate protein kinase C. Strictly speaking, not the same as a co carcinogen, which is defined as being active when administered at the same time. Tumour promoters generally are carcinogens when tested more stringently.
(18 Nov 1997)
tumour registry Recorded information about the status of patients with tumours. Although a registry was originally the place (like registry house in edinburgh) where information was collected (in registers), the word registry has also come to mean the collection itself. A tumour registry is organised so the data can be analyzed. For example, analysis of data in a tumour registry maintained at a hospital may show a rise in lung cancer among women.
(12 Dec 1998)
tumour specific antigen <immunology, oncology> Antigen on tumour cells detected by cell-mediated immunity. For virus transformed cells TSTA (unlike T antigen) is found to differ for different individual tumours induced by the same virus. May consist of fragments of T antigens exposed at the cell surface.
(18 Nov 1997)
tumour-specific transplantation antigens Surface antigen's of DNA tumour virus-transformed cells, which elicit an immune rejection of the virus-free cells when transplanted into an animal that has been immunised against the specific cell-transforming virus.
(05 Mar 2000)
tumour stage <oncology> The extent of the spread of a malignant neoplasm from its site of origin.
See: TNM staging.
(05 Mar 2000)
tumour stem cells <cell biology> Colony-forming cells which give rise to neoplasms.
(12 Dec 1998)
tumour suppressor <molecular biology, oncology> A gene that encodes a product that normally negatively regulates the cell cycle and that must be mutated or otherwise inactivated before a cell can proceed to rapid division.
Examples: p53, RB retinoblastoma), WT 1 (Wilm's tumour), DCC (deleted in colonic carcinoma), NF 1 (neurofibrosarcoma) and APC adenomatous polyposis coli).
(18 Nov 1997)
tumour virus <oncology, virology> Virus capable of inducing tumours.
(18 Nov 1997)
tumour viruses, murine Species of mammalian type c retroviruses (retroviruses type c, mammalian) that cause solid tumours or leukaemias in mice.
(12 Dec 1998)
tumour virus infections Infections produced by oncogenic viruses. The infections caused by DNA viruses are less numerous but more diverse than those caused by the RNA oncogenic viruses.
(12 Dec 1998)
turban tumour Cylindroma of the scalp which, when overgrown, may resemble a turban.
(05 Mar 2000)
Ewing's tumour A malignant primary bone tumour that arises most commonly in the first three decades of life. It is highly malignant (prone to spread) and often requires treatment with some combination of radiation therapy and chemotherapy.
(27 Sep 1997)
faecal tumour An accumulation of inspissated faeces in the colon or rectum giving the appearance of an abdominal tumour.
Synonym: faecal tumour, fecaloma, scatoma, stercoroma.
Origin: copro-+ G. -oma, tumour
(05 Mar 2000)
yaba monkey tumour virus The type species of yatapoxvirus, a tumour-producing DNA virus discovered in monkeys in yaba, nigeria. It has been found to produce histiocytomas in monkeys and humans.
(12 Dec 1998)
Yaba tumour <oncology, virology> A poxvirus-induced neoplasm of African monkeys caused by the Yaba monkey virus, a member of the family Poxviridae.
It is associated with tumour-like growths occur chiefly on the head and limbs. The tumours are benign and the natural disease has been reported only in Africa in monkeys kept outdoors.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
ÅëÇÕ°Ë»ö ¿Ï·á